Novavax, Inc. (NASDAQ:NVAX) on June 23 announce that it has been recognized as one of The Washington Post Top Workplaces. The Washington Post Top Workplaces are determined based solely on employee feedback. The employee survey was conducted by WorkplaceDynamics, LLP, a leading research firm on organizational health and employee engagement. Over the past year, more than 5,000 organizations in the U.S. have turned to WorkplaceDynamics to better understand what’s on the minds of their employees. Through its workplace improvement offerings, WorkplaceDynamics provides solutions, training and tools to help clients improve their workplace. Novavax, Inc. (NASDAQ:NVAX) net profit margin is – and weekly performance is -3.70%. On last trading day company shares ended up $4.68. Analysts mean target price for the company is $11.00. Novavax, Inc. (NASDAQ:NVAX) distance from 50-day simple moving average (SMA50) is 3.26%.
Acasti Pharmaceuticals Inc. (NASDAQ:ACST) surged Wednesday after the biopharmaceutical company announced it had completed two trials. The company, which focuses developing krill oil-based forms of omega-3 phospholipid therapies for treating and preventing cardiometabolic disorders, said it completed the Phase II, double-blind, placebo-controlled TRIFECTA study and the Pharmacokinetic PK trial. These results would be crucial in Acasti’s talks with the FDA on approval to conduct a Phase III trial in the U.S. Acasti Pharma Inc. (NASDAQ:ACST) shares advanced 7.57% in last trading session and ended the day on $1.08. Acasti Pharma Inc. (NASDAQ:ACST) quarterly performance is -5.26%.
Oppenheimer cut shares of Karyopharm Therapeutics (NASDAQ:KPTI) from an outperform rating to a market perform rating in a research note issued to investors on Monday, TheFlyOnTheWall.com reports. Karyopharm Therapeutics Inc. (NASDAQ:KPTI) shares moved up 5.47% in last trading session and was closed at $38.01, while trading in range of $35.72 – $38.69. Karyopharm Therapeutics Inc. (NASDAQ:KPTI) year to date (YTD) performance is 65.84%.
On 7 July Compugen Ltd (NASDAQ:CGEN) disclosed that it has achieved the initial milestone in the cancer immunotherapy collaboration it entered last year with Bayer HealthCare (Bayer). The collaboration provides for the development and commercialization of therapeutic antibodies against two checkpoint protein candidates discovered by Compugen. Compugen Ltd. (USA) (NASDAQ:CGEN) ended the last trading day at $8.94. Company weekly volatility is calculated as 4.45% and price to cash ratio as 3.60.Compugen Ltd. (USA) (NASDAQ:CGEN) showed a negative weekly performance of -3.35%.
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) on 1st July announced that it has acquired the NDA for Lithobid® (lithium carbonate extended release 300 mg tablets) from Noven Therapeutics, LLC. Total consideration for the product was $12 million including an $11 million upfront payment and a $1 million future milestone payment. ANI Pharmaceuticals Inc. (NASDAQ:ANIP) net profit margin is -3.70% and weekly performance is -4.56%. On last trading day company shares ended up $35.41. Analysts mean target price for the company is $40.00. ANI Pharmaceuticals Inc. (NASDAQ:ANIP) distance from 50-day simple moving average (SMA50) is 7.89%.